New developments with bortezomib in treating multiple myeloma.
Reddy
G Kesava
GK
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001897:Boronic Acids / Q000627:therapeutic use*; D000069286:Bortezomib; D002455:Cell Division; D004317:Doxorubicin / Q000008:administration & dosage; D019337:Hematologic Neoplasms / Q000188:drug therapy; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy; D008081:Liposomes; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy; D009101:Multiple Myeloma / Q000188:drug therapy*; D010523:Peripheral Nervous System Diseases / Q000139:chemically induced; D011092:Polyethylene Glycols / Q000378:metabolism; D011719:Pyrazines / Q000627:therapeutic use*; D051437:Renal Insufficiency / Q000188:drug therapy; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D001897:Boronic Acids; D008081:Liposomes; D011719:Pyrazines; D011092:Polyethylene Glycols; D000069286:Bortezomib; D004317:Doxorubicin